Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib) plus abiraterone and…
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)…
Bristol Myers Squibb Announces Leadership Transition Plan Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner,…
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call…
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting AbbVie (NYSE: ABBV) today announced positive data from its Phase…
WHO releases first-ever Standard on universal access to rapid TB diagnostics The World Health Organization (WHO) has just released for the first-time – the WHO standard: Universal access to rapid tuberculosis diagnostics, setting benchmarks to: achieve universal access to WHO-recommended rapid diagnostics…
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00…
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger…
AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14…
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw…
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 / New preclinical data on Bayer’s…
Elisabeth Moreno to join Sanofi’s Diversity, Equity and Inclusion Board Sanofi announces the appointment of Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years.…